Search research articles
Contact Us
Filters
Showing results (461-470 of 567) with videos related to
Page
of 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
David F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.
European Urology
|
July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Brian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
JAMA Oncology
|
December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas Powles, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes
Wenxin Xu, Valerie Gaborieau, Samuel M Niman, et al.
Plos One
|
March 22, 2007
Multiple antimicrobial resistance in plague: an emerging public health risk
Timothy J Welch, W Florian Fricke, Patrick F McDermott, et al.
The Science of the Total Environment
|
September 25, 2023
A comparison of methods to detect low levels of Salmonella enterica in surface waters to support antimicrobial resistance surveillance efforts performed in multiple laboratories
Autumn L Kraft, Jim E Wells, Jonathan G Frye, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Page
of 57
Search research articles
Search
Showing results (461-470 of 567) with videos related to
Sort By:
Page
of 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
David F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.
European Urology
|
July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Brian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
JAMA Oncology
|
December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas Powles, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes
Wenxin Xu, Valerie Gaborieau, Samuel M Niman, et al.
Plos One
|
March 22, 2007
Multiple antimicrobial resistance in plague: an emerging public health risk
Timothy J Welch, W Florian Fricke, Patrick F McDermott, et al.
The Science of the Total Environment
|
September 25, 2023
A comparison of methods to detect low levels of Salmonella enterica in surface waters to support antimicrobial resistance surveillance efforts performed in multiple laboratories
Autumn L Kraft, Jim E Wells, Jonathan G Frye, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Page
of 57